VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ISHL12 2022 | Updates on the use of brentuximab vedotin in later-stage HL

Stephen Ansell, MD, PhD, Mayo Clinic, Rochester, MN, briefly shares some updates on the use of brentuximab vedotin for the treatment of later-stage Hodgkin lymphoma (HL), highlighting the recent overall survival (OS) advantage demonstrated in the ECHELON-1 trial (NCT01712490). This interview took place at The 12th International Symposium on Hodgkin Lymphoma (ISHL12), held in Cologne, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Research funding from Seattle Genetics, BMS, Affimed, Regeneron, Takeda, AstraZeneca, Pfizer, ADC Therapeutics to my institution for clinical trials.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter